CRL EVP Sells 4,179 Shares for $1.08M After Earnings Beat

Insider transactions often serve as a real-time sentiment gauge for institutional investors tracking CRL. Victoria Creamer's $1.08 million sale—executed August 6, one day after the company beat EPS by $0.25—raises the question of whether executives are cashing out near a 52-week high. Here's what the Form 4 and following price action reveal.

Charles River Laboratories International, Inc. (NYSE: CRL) is in the spotlight after Executive Vice President Victoria Creamer sold 4,179 shares on August 6, 2026, one day after the company reported second-quarter earnings that beat Wall Street estimates. The insider sale, disclosed in a Form 4 filing, was executed at an average price of $259.16, generating $1,083,029.64 in proceeds. Following the transaction, Creamer directly held 30,051 shares worth approximately $7.79 million, a 12.21% reduction in her ownership stake. The timing and size of the sale have drawn attention because CRL shares subsequently gained $8.85 to trade at $276.34 during midday trading on Monday, August 10, pushing the stock toward the upper end of its 52-week range.

“

CRL traded at $276.34 on August 10, up $8.85, and remains above its 50-day simple moving average of $214.85 and its 200-day simple moving average of $189.04.

CRL delivered earnings per share of $3.02 for the quarter, beating the consensus estimate of $2.77 by $0.25. Quarterly revenue came in at $1.00 billion, exceeding analyst expectations of $980.53 million but declining 2.7% on a year-over-year basis. In the same quarter last year, the company posted EPS of $3.12, so the headline beat masks a modest year-over-year earnings decline. The company reported a positive return on equity of 15.75% but a negative net margin of 5.96%, and its trailing price-to-earnings ratio of -56.98 reflects a GAAP net loss over the past twelve months. A forward-looking PEG ratio of 2.77 suggests that analysts expect a return to profitability, while a beta of 1.38 indicates the stock carries significantly more volatility than the broader market.

Insider sales are often interpreted as a cautious signal, but the context here is important. The 4,179 shares sold represent only about 0.41% of Monday's trading volume of 1,025,309 shares, and Creamer still directly owns 30,051 shares. This is not a complete exit, and the filing does not state whether the transaction was made under a pre-arranged 10b5-1 trading plan or on a discretionary basis. Nevertheless, the 12.21% reduction in her personal stake is meaningful enough to note, particularly because it came immediately after an earnings beat and while the stock was trading near its 52-week high of $277.07. Selling at $259.16, Creamer did not capture the full subsequent move to $276.34, but the sale still occurred after a substantial rebound from the stock's 52-week low of $144.26.